Inactive Instrument

Aviragen Therapeutics Inc Nasdaq

Equities

US0537611024

Biotechnology & Medical Research

Aviragen Therapeutics to Present at Stifel 2016 Healthcare Conference

November 09, 2016 at 04:02 pm EST

ATLANTA, Nov. 09, 2016 (GLOBE NEWSWIRE) -- Aviragen Therapeutics, Inc. (NASDAQ:AVIR), a pharmaceutical company that is developing the next generation of antivirals, today announced that Aviragen’s CFO & Executive Vice President Mark Colonnese will present a corporate overview at the Stifel 2016 Healthcare Conference on Wednesday, November 16, 2016 at 2:15pm ET in New York.

A live webcast of the presentation can be accessed under "Events and Presentations" in the Investors section of the Company's website at www.aviragentherapeutics.com or at http://wsw.com/webcast/stifel5/avir.

About Aviragen Therapeutics, Inc.

Aviragen Therapeutics is focused on the discovery and development of the next generation of direct-acting antivirals to treat infections that have limited therapeutic options and affect a significant number of patients globally. The Company has three product candidates in active clinical development: vapendavir, an oral treatment for human rhinovirus (HRV) upper respiratory infections in moderate-to-severe asthmatics currently being evaluated in the Phase 2b SPIRITUS trial; BTA585, an oral fusion protein inhibitor in Phase 2 development for the treatment and prevention of respiratory syncytial virus (RSV) infections; and BTA074, a topical antiviral treatment in Phase 2 development for condyloma caused by human papillomavirus types 6 & 11. For additional information about the Company, please visit www.aviragentherapeutics.com.

Contacts:

Mark Colonnese
Executive Vice President and Chief Financial Officer
Aviragen Therapeutics, Inc.
(678) 221-3381                                   
mcolonnese@aviragentherapeutics.com

Beth DelGiacco
Stern Investor Relations, Inc.
(212) 362-1200
beth@sternir.com

Primary Logo

Latest news about Aviragen Therapeutics Inc

Vaxart, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14	CI
Transcript : Vaxart, Inc., 2023 Earnings Call, Mar 14, 2024	Mar. 14
Vaxart Appoints Steven Lo as Chief Executive; Shares Fall	Mar. 06	MT
Vaxart, Inc. Announces Chief Executive Officer Changes	Mar. 06	CI
Vaxart, Inc. Announces Management Appointments	Mar. 06	CI
North American Morning Briefing : Stock Futures -2-	Feb. 01	DJ
B. Riley Upgrades Vaxart to Buy From Neutral, Lifts PT to $2 From $1.50	Jan. 31	MT
Vaxart Secures $9.3 Million Award for Phase 2b COVID-19 Pill Study	Jan. 19	MT
Vaxart to Raise $10 Million From RA Capital Management; Shares Rise	Jan. 16	MT
Vaxart, Inc. Announces CEO Changes	Jan. 16	CI
Vaxart, Inc. Announces Resignation of Andrei Floroiu as President and Director	Jan. 16	CI
Vaxart, Inc. Announces Last Subject Dosed in Phase 1 Trial of Its Norovirus Vaccine Candidate in Lactating Mothers	Dec. 21	CI
Transcript : Vaxart, Inc., Q3 2023 Earnings Call, Nov 02, 2023	Nov. 02
Vaxart, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
Earnings Flash (VXRT) VAXART Posts Q3 Revenue $2.1M	Nov. 02	MT
Vaxart Doses First Subject in Phase 1 Trial of its Norovirus Vaccine Candidate in Lactating Mothers	Nov. 02	CI
Vaxart Says Topline Data From Phase 2 Challenge Study of Monovalent Norovirus Vaccine Meets 5 of 6 Endpoints	23-09-06	MT
Transcript : Vaxart, Inc. - Special Call	23-09-06
Vaxart Announces Topline Data from the Phase 2 Challenge Study of Its Monovalent Norovirus Vaccine Candidate	23-09-06	CI
Cantor Fitzgerald Adjusts Price Target on Vaxart to $4 From $6, Maintains Overweight Rating	23-08-07	MT
Vaxart, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Transcript : Vaxart, Inc., Q2 2023 Earnings Call, Aug 03, 2023	23-08-03
Earnings Flash (VXRT) VAXART Reports Q2 Revenue $1.4M, vs. Street Est of $0.08M	23-08-03	MT
Certain Warrants of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI
Certain Restricted Stock Units of Vaxart, Inc. are subject to a Lock-Up Agreement Ending on 23-JUL-2023.	23-07-22	CI

Chart Aviragen Therapeutics Inc

Duration

Period

More charts

Company Profile

Vaxart, Inc. is a clinical-stage biotechnology company that is primarily focused on the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology (VAAST) proprietary oral vaccine platform. Its vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Its development programs include pill vaccines designed to protect against norovirus (cause for acute gastroenteritis), coronavirus, including SARS-CoV-2 (COVID-19)), and influenza. In addition, it has generated preclinical data for its therapeutic vaccine candidate targeting cervical cancer and dysplasia caused by human papillomavirus. The Company's platform technology employs a vector-based approach and consists of various components, such as a vector (adenovirus type 5 (Ad5); an antigen (Ad5 DNA); an adjuvant (Toll-like receptor 3 (TLR3)), and its proprietary enteric-coated tablet.

Sector

Biotechnology & Medical Research

Calendar

2024-05-07 - Q1 2024 Earnings Release (Projected)

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	-3.33%	102B
REGENERON PHARMACEUTICALS, INC.	+2.29%	96.84B
ARGENX SE	-0.44%	21.48B
BIONTECH SE	-18.50%	20.82B
GENMAB A/S	-7.45%	18.6B
WUXI APPTEC CO., LTD.	-40.70%	16.81B
BEIGENE, LTD.	-25.89%	13.78B
NEUROCRINE BIOSCIENCES, INC.	+0.87%	13.4B
SAREPTA THERAPEUTICS, INC.	+21.39%	11.06B

Bio Therapeutic Drugs